Aerie Pharmaceuticals Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Aerie Pharmaceuticals stock.
View analyst ratings for Aerie Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Aerie Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aerie Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Aerie Pharmaceuticals.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released its quarterly earnings data on Tuesday, May, 4th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.03. The firm earned $22.97 million during the quarter, compared to analysts' expectations of $23.35 million. Aerie Pharmaceuticals had a negative trailing twelve-month return on equity of 337.04% and a negative net margin of 205.13%.
View Aerie Pharmaceuticals' earnings history.

Aerie Pharmaceuticals' stock was trading at $14.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AERI stock has increased by 6.7% and is now trading at $15.52.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 12-month price objectives for Aerie Pharmaceuticals' shares. Their forecasts range from $9.00 to $32.00. On average, they expect Aerie Pharmaceuticals' stock price to reach $24.14 in the next year. This suggests a possible upside of 55.6% from the stock's current price.
View analysts' price targets for Aerie Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aerie Pharmaceuticals include Bavarian Nordic A/S (BVNRY), NanoString Technologies (NSTG), Vericel (VCEL), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Revolution Medicines (RVMD), Rubius Therapeutics (RUBY), bluebird bio (BLUE), Kymera Therapeutics (KYMR), Instil Bio (TIL), C4 Therapeutics (CCCC), Immunocore (IMCR), Sangamo Therapeutics (SGMO), BioAtla (BCAB) and Translate Bio (TBIO).
View all of AERI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

Aerie Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Woodline Partners LP (4.60%), William Blair Investment Management LLC (3.49%), Schroder Investment Management Group (3.01%), Citigroup Inc. (2.50%), C WorldWide Group Holding A S (2.47%) and Fred Alger Management LLC (2.10%). Company insiders that own Aerie Pharmaceuticals stock include Casey C Kopczynski, Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Gerald D Cagle, Richard J Rubino and Vicente Anido Jr.
View institutional ownership trends for Aerie Pharmaceuticals.

AERI stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Granite Investment Partners LLC, State of Wisconsin Investment Board, DnB Asset Management AS, Millennium Management LLC, Citigroup Inc., Renaissance Technologies LLC, and Pinnacle Associates Ltd..
View insider buying and selling activity for Aerie Pharmaceuticals or view top insider-selling stocks.

AERI stock was purchased by a variety of institutional investors in the last quarter, including Woodline Partners LP, Principal Financial Group Inc., Principal Financial Group Inc., Rubric Capital Management LP, Clearbridge Investments LLC, Levin Capital Strategies L.P., Integral Health Asset Management LLC, and William Blair Investment Management LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP, Foresite Capital Management Ii, Richard J Rubino, and Vicente Anido Jr.
View insider buying and selling activity for Aerie Pharmaceuticals or or view top insider-buying stocks.

Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AERI stock can currently be purchased for approximately $15.52.

Aerie Pharmaceuticals has a market capitalization of $727.78 million and generates $83.14 million in revenue each year. The company earns $-183,100,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis.

Aerie Pharmaceuticals employs 365 workers across the globe.

The official website for Aerie Pharmaceuticals is www.aeriepharma.com.

Aerie Pharmaceuticals is headquartered at 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703.

Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The company can be reached via phone at 919-237-5300 or via email at [email protected]